Tainkang: Wholly-owned subsidiary Baricitinib tablets win the bid in the twelfth national centralized drug procurement.

Tian Kangkang announced that recently, its wholly-owned subsidiary Huabo Kaisheng participated in the twelfth batch of national centralized drug procurement, and Baricitinib tablets were selected. During the procurement period, medical institutions will prioritize the use of selected products. After Huabo Kaisheng signs contracts and implements them, it will benefit product volume expansion and market development, enhance brand influence, and have a positive impact on future performance. However, there are uncertainties regarding the signing of procurement agreements and other subsequent matters and their impact on performance.